Streetbeat News

Revenues

CCCS

Four financial analysts have recently shared their diverse evaluations of CCC Intelligent Solutions (NASDAQ:CCCS), ranging from bullish to bearish. The average 12-month price target for CCCS has been raised to $13.5, reflecting a 3.85% increase from the previous target of $13.00. Analysts from Barrington Research, Barclays, and Citigroup have updated their ratings and price targets, indicating a mixed outlook on the company's performance. CCC Intelligent Solutions, a provider of cloud, mobile, AI, and other technologies for the insurance economy, has shown a revenue growth of 11.28% over the past three months but struggles with profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 6:01 pm

PAYO

Over the last three months, Payoneer Global (NASDAQ:PAYO) received mixed analyst ratings, with a recent shift towards a somewhat bullish outlook. The average 12-month price target is now $7.00, down from $7.33, indicating a 4.5% decrease. Analysts from firms like Keefe, Bruyette & Woods, Needham, Benchmark, and Goldman Sachs have updated their ratings and price targets, reflecting changes in market conditions and company performance. Payoneer Global's financial performance shows a solid revenue growth rate of 30.91% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its below-industry-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 6:00 pm

RNLX

Renalytix plc (NASDAQ:RNLX) announced the U.S. Government's approval to add its kidneyintelX.dkd test to a 10-year Governmentwide Acquisition Contract for early-stage kidney disease testing, effective March 1, 2024. The test is priced at $950 per result. This contract allows for testing services at any government healthcare facility, including the U.S. Veterans Administration and Department of Defense. Additionally, Medicare's consideration of a coverage policy for KidneyIntelX could lead to insurance reimbursement for millions of patients. RNLX shares surged 32.50% to $1.10.

Portfolio Pulse from Vandana Singh

February 29, 2024 | 5:51 pm

AXNX

Analysts have mixed views on Axonics (NASDAQ:AXNX), with recent ratings varying from bullish to bearish. The average 12-month price target for AXNX has slightly increased to $71.29. Axonics, a medical technology company, has shown positive financial performance, including a revenue growth rate of 32.27% and a net margin of 4.22%. The company's market capitalization is below industry benchmarks, but it has demonstrated strong profitability and effective cost control.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

VSTS

Analyst ratings for Vestis (NYSE:VSTS) have varied over the past three months, with recent updates showing a shift towards a more bearish outlook. The average 12-month price target has increased to $21.00 from $17.00, indicating a positive sentiment shift. Vestis, a provider of uniform rentals and workplace supplies, has shown a revenue growth of 2.46% but struggles with profitability and debt management. The company's market capitalization is below the industry average, suggesting it is smaller compared to peers.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

PRVA

Privia Health Gr (NASDAQ:PRVA) has been evaluated by 4 analysts over the last three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $25.25, a decrease from the previous $28.33. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Privia Health Gr, a technology-driven physician-enablement company, shows strong net margin and ROE but lags in revenue growth and ROA compared to industry peers. Its market capitalization and debt management indicate a smaller scale and conservative financial approach.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

GPOR

Gulfport Energy (NYSE:GPOR) has received mixed analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target for GPOR has been raised to $154.6, indicating a slight increase from the previous target. Financial analysis reveals challenges in revenue growth and market capitalization but highlights strong profitability metrics such as net margin, ROE, and ROA. GPOR's debt management is also noted positively.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

EDIT

Editas Medicine (NASDAQ:EDIT) has seen a positive shift in analyst ratings over the last three months, with an average 12-month price target now at $14.00, up 27.27% from $11.00. Analysts from Citigroup, Barclays, JP Morgan, and Truist Securities have all raised their price targets, reflecting optimism about the company's future performance. Editas Medicine, a genome editing company, has shown remarkable financial health with a revenue growth rate of 12604.76% as of September 30, 2023, and strong market capitalization, net margin, ROE, and ROA figures.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

RLJ

RLJ Lodging (NYSE:RLJ) has been analyzed by 5 analysts, showing a mix of bullish to indifferent sentiments. Recent ratings reveal an average 12-month price target of $14.1, marking a 10.59% increase from the previous target. Analysts from Oppenheimer, Wolfe Research, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, reflecting optimism. Despite this, RLJ faces revenue challenges, with a -4.4% growth over 3 months, and struggles in profitability and asset utilization, indicated by low net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

BCO

SAEF

Brink's Company (NYSE:BCO) reported Q4 fiscal 2023 earnings with a 5% year-on-year sales growth to $1.246 billion, slightly missing analyst estimates. Adjusted EPS of $2.76 exceeded expectations. Revenue varied across regions, with North America seeing a decrease, while Latin America and Europe experienced growth. Adjusted operating profit and EBITDA saw year-on-year increases. The company has set optimistic targets for FY24, expecting mid-single digit revenue growth and adjusted EPS of $7.30 - $8.00. The Schwab Ariel ESG ETF (NYSE:SAEF), with 3% exposure to Brink's, gained about 5% last month. BCO shares were up 2.5% following the announcement.

Portfolio Pulse from Anusuya Lahiri

February 29, 2024 | 4:56 pm